& Abstract
Background: Factors such as age, gender, and genetic polymorphisms may explain individual differences in pain phenotype. Genetic associations with pain sensitivity have previously been investigated in osteoarthritis patients, with a focus on the P2X7, TRPV1, and TACR1 genes. However, other genes may play a role as well. Osteoarthritis is a common joint disease, and many patients suffering from this disease are thought to have increased sensitivity to noxious stimuli resulting from sensitization in the nociceptive system. The aim of this study was to investigate if genetic variants of mu, kappa, and delta opioid receptor genes (OPRM1, OPRK1, and OPRD1) and the catechol-Omethyltransferase gene (COMT) influenced the pain phenotype in patients with osteoarthritis. Methods: The frequencies of 17 polymorphisms were examined. Pain sensitivity was assessed preoperatively by (1) hip rotation, (2) contact heat stimulation, (3) conditioned pain modulation effect, and (4) pressure stimulation at the tibia in both the affected and the unaffected leg. Results: Ninety-two patients (mean age 66 years) with unilateral hip osteoarthritis were included in the study. Carriage of the OPRM1 rs589046T allele was found to be associated with increased pain ratings during hip rotation (P = 0.04) and increased conditioned pain modulation (P = 0.049). Carriage of the OPRD1 rs2234918C allele was found to be associated with an increased pain detection threshold to contact heat stimulation (P = 0.001). No other associations were found (all P > 0.05).
Conclusion:
Results from the present study suggest that, in patients with hip osteoarthritis, genetic variants in OPRM1 and OPRD1 may contribute to the pain phenotype. &
INTRODUCTION
Osteoarthritis (OA) is the most common joint disease worldwide. 1 Many patients with OA are thought to have increased sensitivity to noxious stimuli resulting from sensitization in the nociceptive system. 2 Age, gender, height, and genetic polymorphisms are some factors that may explain individual differences in pain sensitivity. [3] [4] [5] [6] Human genetic association studies have provided insight into the interindividual variability in pain sensitivity. [7] [8] [9] [10] For example, P2X7, TRPV1, and TACR1
genes have been studied in OA patients. [11] [12] [13] However, other genes may also play a role, such as rs4680A/G and rs6269A/G in the COMT gene. 14, 15 Additionally, single nucleotide polymorphisms (SNPs) in the mu, kappa, and delta opioid receptor genes (OPRM1, OPRK1, OPRD1) have been shown to alter pain sensitivity through variations in receptor function. 8, 16, 17 However, findings are still inconclusive. Inconclusive results may be explained by the different methodologies used. 7 Moreover, sociopsychological confounders may blur the findings in the clinical setting. Such confounders can be avoided in studies using experimentally induced pain in healthy volunteers. 18 On the other hand, it is not possible to reproduce the full complexity of clinical pain, and external validity may be limited. 19 Thus, using a combination where experimentally noxious stimuli are induced in patients suffering from pain might be advantageous when trying to elucidate the genetic factors influencing pain sensitivity. In patients with OA, the inflammation process causes peripheral sensitization (the primary afferent neurons in the joint are sensitized) and central sensitization (neurons in the central nervous system receiving input from the inflamed joint are hyperexcitable and undergo neuroplastic changes). 20 The influence of inflammation on pain perception can therefore be investigated by applying experimentally induced pain in these patients. Additionally, it is possible to induce an acute clinical pain by, for example, rotating the hip.
We hypothesized that application of experimental pain models in a clinical setting would elucidate whether carriers of the minor alleles of COMT, OPRM1, OPRK1, or OPRD1 have altered pain sensitivity as compared to noncarriers. Thus, the aims were to compare the following variables in the 2 groups (carriers vs. noncarriers): (1) clinical pain rating during hip rotation; (2) pain reported during contact heat stimulation of the forearm; (3) conditioned pain modulating (CPM) effect; and (4) pain pressure threshold at the tibia distal to the affected and unaffected hip for each polymorphism separately.
METHODS
The trial was conducted by the Department of Pain Medicine, Clinic for Anesthesiology, University Hospital, Georg-August-University of G€ ottingen, Germany, and the Department of Anesthesiology and Intensive Care, Annastift, Hannover, Germany, between April and August 2013. The study was approved by the ethical committees of the University Hospital of G€ ottingen (No. 5/4/12) and the Medical School Hannover (No. 1483-2012). Written informed consent was obtained from the patients before the study procedures commenced. The study was carried out according to the recommendations of the Helsinki Declaration (2013). Patient recruitment and pain assessments were performed at the Annastift, Hannover. Results regarding the primary endpoints from the study have been published previously. 21 This article concerns the secondary endpoint of the protocol.
Patients
The included patients suffered from hip OA and were scheduled to undergo total hip replacement surgery. A total of 175 patients were screened for participation. Inclusion criteria were (1) older than 18 years; (2) capacity to give consent on his/her own; and (3) sufficient knowledge of the German language to understand the study information and the required questionnaires. Exclusion criteria were (1) severe neurological disease; (2) severe psychiatric disease such as major depression or schizophrenia, or active drug abuse; (3) a high dose of opioid therapy (> 30 mg oral morphine equivalent dose per day); or (4) participation in other studies conducted at the same time.
Procedure
Patients were usually admitted to hospital on the day before surgery. Thus, patients were recruited on the morning of the day prior to surgery. After consent was obtained, the pain history was registered, followed by completion of the questionnaires (during the waiting time between hospital procedures). Functional testing and pain assessments were conducted on the afternoon of the preoperative day ( Figure 1 ).
Patients refrained from smoking and from drinking coffee or other caffeine-containing beverages 1 to 2 hours prior to the assessment of pain sensitivity. Additionally, the patients were familiarized with the various procedures and given standardized test instructions. To avoid investigator emerging biases, all psychophysiological measurements were done by the same researcher. Opioid consumption (substance and dose) was registered for each patient.
Passive Hip Rotation. The perceived intensity of evoked pain with passive rotation of the hip scheduled for replacement was assessed on an 11-point numeric rating scale (NRS), where 0 indicated "no pain" and 10 indicated "worst imaginable pain." First, the hip was brought into a 90°flexed position, with the knee flexed at 90°at the same time, and then slowly rotated interiorly until the patient reported the first onset of pain, the pain detection threshold (PDT). Then, passive rotation was continued until the pain threshold was reached, and this position was maintained for 30 seconds. Afterwards, the patients were asked to rate the evoked pain on an NRS, and this value was used for further analysis. In patients who could not tolerate this choreography (ie, with severe pain upon hip flexion), hip flexion was used as the stimulus.
Quantitative Sensory Testing. Contact heat stimulation -Contact heat stimulation was determined by a computer-driven heat pain device (TSA-II NeuroSensory Analyzer; Medoc Ltd, Ramat Yishai, Israel). A thermode was applied to the volar surface of the dominant forearm at 10 cm from the elbow. The temperature was increased gradually from 32°C to a maximum of 52°C at a rate of 1°C/second until the patient reached the PDT. The stimulation was stopped when the patient clicked a button. Four consecutive temperature measurements were performed, and the average of the preceding 3 PDTs was computed and retained for further analysis.
Conditioned pain modulation (CPM) effect -To assess descending inhibitory pain modulation, a CPM paradigm was carried out. CPM was measured as the change in pain sensitivity to a test stimulus before (pre-CPM) and during (peri-CPM) a conditioned pain stimulus. 22 The conditioned pain stimulus was performed in the following way: The patient's hand was immersed in cooled water (around 8°C) for 2 minutes, or less if the pain was intolerable for the patient. Contact heat PDTs were repeated at 60, 90, and 120 seconds after immersion of the hand in cold water. The CPM effect was calculated for the PDT to contact heat stimulation as the percentage change from baseline (eg, [T120 min À baseline]/baseline*100%). The time point with the highest CPM effect was used for further analysis.
Pressure pain detection threshold -The pressure pain threshold was assessed at the tibial bone, 15 cm below the patella. A handheld electronic pressure algometer (Somedic AB, Stockholm, Sweden) was used. The pressure rate was gradually increased with 30 kPa/ second until the patients reported the PDT. The maximum pressure intensity applied was 1,000 kPa. Altogether, 4 measurements were recorded in short succession. The mean pressure intensity (kPa) at the PDT was calculated as the mean of the preceding 3 measures and was used for further analysis.
DNA Extraction and Genotyping
Genomic DNA was extracted from an aliquot of venous blood using the QIAsymphony DSP DNA Midi kit (Qiagen, Copenhagen, Denmark) and the QIAsym-
51T/C, rs7836120A/G, rs6473799T/C, rs1365098G/T, rs7824175G/C, rs963549G/A), and OPRD1 (rs533123 G/A, rs2236857T/C, rs2234918C/T) were genotyped using predesigned TaqMan SNP genotyping assays on a StepOne Plus real-time instrument (Applied Biosystems, Foster City, CA, U.S.A.). Genotyping was conducted in accordance with the manufacturer's protocol. The choice of candidate SNPs was based on location along the gene (ie, SNPs in regions most likely to have an impact on gene function were selected) and the existence of published data for the specific SNPs. Thus, within each selected gene, SNPs were selected in an attempt to cover the allelic diversity.
Statistical Analysis and Considerations
The chi-square goodness-of-fit test (Haploview version 4.2; Broad Institute, Cambridge, MA, U.S.A.) was used to determine if all genotype frequencies were in HardyWeinberg equilibrium. The demographic characteristics for all patients are presented as medians with 25th to 75th percentiles. The demographic characteristics for carriers and noncarriers of the minor alleles were both visually inspected as histograms with corresponding normal curve and analyzed by the Shapiro-Wilk test for normality (P < 0.05 indicates non-normally distributed data). Age, weight, and body mass index (BMI) were non-normally distributed, and the Mann-Whitney U-test was used as a nonparametric test. The height and duration of hip pain were normally distributed and were analyzed using parametric t-tests. Categorical variables such as gender were analyzed by Fisher's exact test. All tested genetic variants were bi-allelic SNPs, and it was unknown whether the variant allele could be a risk-enhancing allele (increases the likelihood of a poorer outcome) or a protective allele (increases the likelihood of improving the outcome). Thus, genotype distributions were calculated for subjects homozygous (AA) and heterozygous (AB) for the A allele (minor allele), and for subjects homozygous (BB) for the B allele (major allele). The genetic association analysis included 2 groups: carriers of the minor allele (AA + AB) and noncarriers of the minor allele (BB). Correction for confounders, such as age, BMI, and duration of hip pain, were not conducted because no difference was seen between carriers and noncarriers of the minor alleles in any genes. However, parametric multiple regressions adjusted for "gender" and "opioid treatment vs. no opioid treatment" were used in the evaluation of the association of genetic variations in OPRM1, OPRD1, OPRK1, and COMT with the investigated assessments of pain sensitivity. No adjustment for multiple testing was performed because the genetic variations are known to be associated with pain sensitivity. 23 All statistical analyses were conducted in STATA version 12.0 (StataCorp, College Station, TX, U.S.A.), and the results are presented as means with corresponding 95% confidence intervals. P < 0.05 was considered significant, and effect sizes are presented as the differences between the means of the 2 groups.
RESULTS
For this study, 112 patients signed the informed consent. Data from 20 of these patients were not included in the final analysis for different reasons, as described in Figure 2 . Thus, data from 92 patients (50 females and 42 males) were included in the analysis. The median age was 66 years, with a range from 58 to 74 years. Their median body mass index was 27 kg/m 2 (25 to 31 kg/m 2 ). Median height and weight were 171 cm (164 to 176 cm; n = 90) and 83 kg (68 to 90 kg; n = 91), respectively.
All investigated SNPs were in Hardy-Weinberg equilibrium. The genotype distribution and corresponding demographic characteristics are presented in Table 1 . The allele frequencies for the SNPs in OPRM1, OPRK1, OPRD1, and COMT were similar to the allele frequencies of the HapMap-CEU project (http://www.ncbi.nlm. nih.gov/projects/SNP/snp_viewTable.cgi?pop=1409). With regard to the OPRM1 rs533586 SNP, the allele frequency was comparable to the allele frequency of the CEU_GENO_PANEL project (http://www.ncbi.nlm. nih.gov/projects/SNP/snp_viewTable.cgi?pop=4720). Furthermore, in this cohort we found that the OPRM1 rs9479757G allele was more frequent than the rs9479757A allele, which was in agreement with results published by Beer et al. 24 Nonetheless, we have previously found the reverse trend in another cohort in rs9479757 allele frequency, showing that the rs9479757A allele was the most frequent. 25 
Pain Sensitivity and Gender
Results for pain sensitivity in males and females are shown in Table 2 . There was a significant association between gender and pressure pain threshold in the unaffected leg because males could tolerate higher pressure than females (P = 0.05). No other associations between gender and pain sensitivity were found (all P > 0.05).
Genetic Associations with Demographic Characteristics
Noncarriers of the OPRM1 rs589046T, OPRM1 rs563649T, or OPRK1 rs1365098T alleles were taller than carriers (172.2 cm vs. 168.3 cm, P = 0.04; 171.3 cm vs. 163.3 cm, P = 0.01; and 172.2 cm vs. 168.3 cm, P = 0.04, respectively) (see Table 1 ). In addition, noncarriers of the OPRM1 rs9479757A allele weighed more than carriers (84 kg vs. 70 kg, P = 0.04). No other SNPs were associated with height or weight (P > 0.05).
Genetic Associations with Pain Sensitivity
Clinical Pain Rating During Hip Rotation. A higher rating of pain intensity (15.6%) was seen in carriers of the OPRM1 rs589046T allele (mean 5. Additionally, an explorative analysis showed that a higher rating of pain intensity was seen in patients in opioid treatment compared with patients not in opioid treatment (P = 0.02).
Heat PDTs. A genetic association was seen between the OPRD1 SNP rs2234918 allele and the PDT to contact heat stimulation (P = 0.001) (see Figure 2, (Figure 4) , indicating lower sensitivity to pain in patients with the C allele. No other SNPs were associated with the contact heat PDT (P > 0.05).
CPM Effect. The most distinct CPM effect was seen 120 seconds after initiation of the cold pressor test. Thus, values at this time point were used for further analysis. A more evident CPM effect (94.7%) was seen in carriers of the OPRM1 rs589046T allele (pre-CPM heat PDT of 46.4°C; peri-CPM heat PDT of 47.1°C; CPM mean of 3.7% [2.5% to 5.0%]; n = 41) compared with noncarriers (pre-CPM heat PDT of 47.9°C; peri-CPM heat PDT of 48.0°C; CPM mean of 1.9% [0.8% to 3.2%]; n = 44; effect size: 1.8; P = 0.05) ( Figure 5 , Table 3 ), indicating a more pronounced pain modulation in patients with the T allele. 
Pressure Pain Threshold
No SNPs were associated with pressure pain threshold at the tibia in either the affected or unaffected hip (P > 0.05) (see Table 3 ).
DISCUSSION
The presented results support the hypothesis that carriage of the minor allele of ORPM1 (rs589046) or OPRD1 (rs2234918) was associated with pain sensitivity in patients with OA of the hip.
Interactions with Demographics
Males tolerated higher pressure in the unaffected leg than females. This confirms results from a previous study, which showed that males could tolerate higher muscle pressure than females. 16 Additionally, sensitivity Demographic characteristics are for the carriers of the minor allele vs. the noncarriers of the minor allele; age, height, weight, and BMI are represented as median (25th to 75th percentiles). Boldfacing indicates that there is a significant difference between carriers of the minor allele and noncarriers of the minor allele.
to pressure has been postulated to be genetically associated with an OPRM1 rs1799971 SNP, but only in males. 26 Recently, height has been suggested to be a classical polygenetic trait associated with newly discovered genetic factors. 27 Additionally, some investigators have suggested that gender differences in body height may be associated with differences in pain sensitivity based on the belief that body height would be inversely related to the density of peripheral nociceptors. 28 For example, results from a previous study showed that height was negatively associated with cold pressorinduced pain thresholds in females. 4 In the present study, we found a difference in height between the carrier group and noncarrier group for the OPRM1 rs589046, OPRM1 rs563649, and OPRK1 rs1365098 SNPs. Thus, for further investigation of interindividual n, number of patients; BMI, body mass index; NRS, numeric rating scale; PDT, pain detection threshold; CPM, conditioned pain modulating. Boldfaced parameters indicate that there was a significant difference between males and females. variability in pain sensitivity, height might be included as a cofactor in the analysis.
Association Between Genetic Factors and Pain
No associations were found between COMT and pain sensitivity. However, results from other studies have demonstrated an association between COMT and pain phenotypes. 7, 14, 29 Only 1 polymorphism of the COMT gene was investigated in the present study, and this may explain the discrepancy, because it has been demonstrated that COMT contains at least 5 functional polymorphisms that impact its biological activity and associated phenotypes. 29 Thus, it cannot be excluded that other COMT polymorphisms are associated with pain phenotype in OA. Carriage of the widely studied OPRM1 rs1799971G allele has been found to be associated with higher thresholds to pressure pain, which indicates a lower pain sensitivity to pressure in participants carrying the G allele. 26 However, despite several reports of positive associations between the rs1799971 SNP of OPRM1 and altered pain sensitivity, based on the results of a meta-analysis of published genetic association studies it was concluded that the rs1799971 SNP is inconsistently associated with altered pain-related phenotypes. 30 Results from the present study and from another study in patients with knee OA 6 also failed to confirm the association between this specific allele and pain sensitivity. However, in the present study, other OPRM1 SNPs were explored, and it was found that the OPRM1 rs589046T allele was associated with increased perceived pain intensity during hip rotation and with a more pronounced CPM effect. These findings are contradictory because a high pain rating is normally associated with poor pain modulation (reduced CPM effect). In summary, the well-studied OPRM1 rs1799971 SNP could not be associated with pain sensitivity in the OA patient population. However, less studied OPRM1 SNPs were found to be associated with pain sensitivity; therefore, for future studies we recommend including several SNPs of the same gene.
In healthy volunteers, it has been demonstrated that carriers of the OPRK1 rs6473799C allele had a higher pain tolerance threshold to mechanical visceral stimulation. 31 Additionally, it has been demonstrated that 2 other OPRK1 SNPs (rs7016778 and rs7824175) are associated with the pain tolerance threshold to muscle pressure stimulation. 16 However, in the present study no associations with OPRK1 SNPs were found. This may be explained by the use of other pain models because specific experimental pain paradigms are controlled by partially distinct nociceptive mechanisms based on the pain-evoking stimuli. It has been suggested that these distinct mechanisms may be influenced by different sets of genes.
32
Results from experimental pain studies in healthy volunteers have shown no differences in pain thresholds to contact heat stimulations between carriers and noncarriers of different OPRD1 SNPs. 16, 31, 33, 34 However, in this study in patients with OA, carriers of the OPRD1 rs2234918C allele reported a higher PDT to contact heat stimulation compared with noncarriers, indicating lower pain sensitivity in patients with the C allele. OPRD1 is thought to be involved in neuropathic and inflammatory pain perception; 35,36 hence, investigating the influence of OPRD1 SNPs on these pain types in clinical studies is recommended.
Gene Selection
The investigated candidate genes were selected based on previous work. 16, 25, 31, 37 Although they are not specific for pain, they may have an impact on pain sensitivity because endogenous opioid-like ligands, enkephalins, interact with opioid receptors, and thereby may modulate the pain system. 38 Catechol-O-methyltransferase has an indirect effect on the mu opioid receptor by changing its activity through enkephalins. 39 In the present study, associations between altered pain sensitivity and variants of the opioid receptor genes (but not for COMT variants) were identified. It has been shown that SNPs other than the 17 in the 4 Figure 5 . Conditioned pain modulating (CPM) effect and the OPRM1 rs589046 single nucleotide polymorphism (univariate analysis). A higher CPM effect was seen in carriers of the OPRM1 rs589046T allele (n = 41) compared with noncarriers (n = 44; effect size: 1.8; P = 0.05).
candidate genes included in this study are associated with pain sensitivity. For example, cold pressor-induced pain sensitivity and OA pain have been previously shown to be associated with an SNP in the P2RX7 receptor gene. 3, 11 Additionally, if epistasis, which is the interaction between genes, is present, the effect of 1 SNP may be altered or masked by the effect of another SNP and thereby may reduce the power to detect genetic associations. Thus, it is difficult to exclude that other nonsignificant SNPs are associated with the assessment of pain sensitivity. Thus, in future studies with higher sample sizes, epistatic effects should be considered. The sample size of this study was relatively small for a genetic association study, but the use of experimental measurements has the potential to minimize factors that may affect detection of true associations. 18 Finally, each SNP was analyzed separately for each investigated assessment of pain sensitivity; therefore, the potential for an additive effect in patients with multiple genetic associations may exist. However, the present study was not designed and powered for a multipoint SNP analysis, as the aim was to investigate separate candidate polymorphisms. Because increased sensitivity to noxious stimuli has been postulated as a risk factor for the development of chronic pain conditions, 14, 40 following surgery it may be important to investigate if genetic polymorphisms can be used to predict the patients at high risk.
External Validity
We showed that using experimentally induced pain stimuli in patients suffering from clinical pain offers a new platform to explore the interindividual differences in pain sensitivity to the actual pain states of interest, relatively free of confounders seen in traditional clinical studies. The investigation of genetic associations with variability in pain sensitivity may be of particular relevance for patients with inflammatory pain disorders, such as OA, because these disorders are characterized by increased pain sensitivity. 20 
CONCLUSION
Results from the present study suggest that, in patients with hip OA, genetic variants in OPRM1 and OPRD1 may contribute to the variability in pain sensitivity. Clinical relevance cannot be confirmed from the present study because many other factors, such as psychological status, may also play a role in individual sensitivity to noxious stimuli. However, the results add information on opioid receptor polymorphisms and indicate that polymorphisms other than the most studied OPRM1 rs1799971 may play an important role.
